Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy

Eur J Cancer. 2019 Jul:115:84-87. doi: 10.1016/j.ejca.2019.04.026. Epub 2019 May 23.

Authors

Collin K Chin¹, Sara Hall¹, Celia Green², Guy Van Hazel³, Dominic Spagnolo⁴, Chan Yoon Cheah⁵

Affiliations

¹ Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Perth, WA, Australia.
² Department of Anatomical Pathology, Pathwest Laboratory Medicine Western Australia, Nedlands, WA, Australia.
³ Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
⁴ Department of Anatomical Pathology, Pathwest Laboratory Medicine Western Australia, Nedlands, WA, Australia; School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia.
⁵ Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Perth, WA, Australia; School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia. Electronic address: chan.cheah@health.wa.gov.au.

PMID: 31129384
DOI: 10.1016/j.ejca.2019.04.026

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Female
Humans
Ipilimumab / administration & dosage
Ipilimumab / adverse effects*
Lymphohistiocytosis, Hemophagocytic / chemically induced*
Lymphohistiocytosis, Hemophagocytic / diagnosis
Lymphohistiocytosis, Hemophagocytic / drug therapy
Lymphohistiocytosis, Hemophagocytic / immunology
Melanoma / drug therapy*
Melanoma / immunology
Melanoma / secondary
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Skin Neoplasms / pathology
Steroids / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Steroids
Nivolumab